254. Porphyria Clinical trials / Disease details
Clinical trials : 70 / Drugs : 54 - (DrugBank : 19) / Drug target genes : 19 - Drug target pathways : 35
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04923516 (ClinicalTrials.gov) | June 2021 | 8/6/2021 | Prevalence of Acute Hepatic Porphyria | Prevalence of Acute Hepatic Porphyria in Population With Suggestive Clinical Picture | Acute Hepatic Porphyria | Other: Dosage of Delta-aminolevulinic acid and Porphobilinogen | Association pour la Recherche en Medecine Interne | NULL | Not yet recruiting | 18 Years | 60 Years | All | 500 | NULL | |
| 2 | NCT00418795 (ClinicalTrials.gov) | June 11, 2003 | 4/1/2007 | Porphozym in the Treatment of Acute Attacks in AIP | A Multi-centre, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial, Investigating the Efficacy and Safety of Porphozym (Recombinant Human Porphobilinogen Deaminase) in the Treatment of Acute Attacks in AIP | Acute Intermittent Porphyria | Drug: recombinant human porphobilinogen deaminase (Porphozym) | Zymenex A/S | NULL | Completed | 18 Years | N/A | All | 36 | Phase 2/Phase 3 | United States |